Evolution of the Quinoline Scaffold for the Treatment of Leishmaniasis: A Structural Perspective

• Type: Another Publication in an International Scientific Journal
• Date: 2024

Authors

Silva, CFM (Author) Other; Pinto, DCGA (Author) Other; Pedro A Fernandes (Author) FCUP; Silva, AMS (Author) Other

Journal

Title: Pharmaceuticals

Vol. 17

Final page: 285

ISSN: 1424-8247

Publisher: MDPI

Indexing

ISI Web of Knowledge - 0 Citations

Scopus - 0 Citations

Other information

Authenticus ID: P-010-7Z2

DOI: 10.3390/ph17030285

Abstract (EN): Since the beginning of the XXI century, Leishmaniasis has been integrated into the World Health Organization's list of the 20 neglected tropical diseases, being considered a public health issue in more than 88 countries, especially in the tropics, subtropics, and the Mediterranean area. Statistically, this disease presents a world prevalence of 12 million cases worldwide, with this number being expected to increase shortly due to the 350 million people considered at risk and the 2-2.5 million new cases appearing every year. The lack of an appropriate and effective treatment against this disease has intensified the interest of many research groups to pursue the discovery and development of novel treatments in close collaboration with the WHO, which hopes to eradicate it shortly. This paper intends to highlight the quinoline scaffold's potential for developing novel antileishmanial agents and provide a set of structural guidelines to help the research groups in the medicinal chemistry field perform more direct drug discovery and development programs. Thus, this review paper presents a thorough compilation of the most recent advances in the development of new quinoline-based antileishmanial agents, with a particular focus on structure-activity relationship studies that should be considerably useful for the future of the field.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 35